In this study, they identified three distinct risk groups of patients based on anatomic site and NUTM1 fusion type, composed by the following: (1) Group A, patients with non-thoracic primary NC and presence of BRD3- or NSD3-NUTM1 fusion, (2) Group B, patients with non-thoracic primary NC and presence of BRD4-NUTM1 fusion, and (3) Group C, patients with thoracic primary NC regardless of the type of NUTM1 fusion. The gene discussed is BRD3; the disease is nevus comedonicus syndrome.